PD
DNTH icon

Point72 (DIFC)’s Dianthus Therapeutics DNTH Stock Holding History

Point72 (DIFC)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$114K Sell
2,901
-6,012
-67% -$154K 0.01% 552
2025
Q2 		$166K Sell
8,913
-7,835
-47% -$147K 0.01% 821
2025
Q1 		$304K Buy
16,748
+2,735
+20% +$60.3K 0.01% 773
2024
Q4 		$305K Buy
14,013
+1,539
+12% +$39.6K 0.01% 774
2024
Q3 		$342K Sell
12,474
-426
-3% -$11.9K 0.01% 740
2024
Q2 		$334K Buy
+12,900
New +$310K 0.01% 747

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 (DIFC)'s DNTH Position: Q3 2025 in Review

Point72 (DIFC) reduced its Dianthus Therapeutics (DNTH) stake by 67% in Q3 2025, selling an estimated $154K and leaving 2,901 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #552.

Point72 (DIFC) first reported a position in DNTH in Q2 2024 and has held it in 6 quarters since. The position peaked at $342K in Q3 2024. 140 funds tracked by Wall St. Rank hold DNTH as of Q3 2025.

  • Point72 (DIFC) held 2,901 shares of Dianthus Therapeutics worth $114K as of Q3 2025.
  • Point72 (DIFC) sold 6,012 Dianthus Therapeutics shares in Q3 2025, an estimated $154K.
  • Dianthus Therapeutics made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #552 holding.
  • Point72 (DIFC) first reported a position in Dianthus Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Point72 (DIFC)'s Dianthus Therapeutics position peaked at $342K in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.